Amneal Pharmaceuticals

Amneal Pharmaceuticals

AMRX· Manufacturing· Fiscal year ends in December

CEO pay in FY2025Stock +59.1% in FY2025

Chintu Patel is the CEO of Amneal Pharmaceuticals and was paid $8.7M in FY2025 (Dec), up 21%.

Pay$100 in the stock at the end of FY20 → $760
CEO pay is from each Amneal Pharmaceuticals proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Executives6

See all
  1. 1Chintu PatelFY2025
  2. 2Chirag PatelFY2025
  3. 3Anastasios KonidarisFY2025
  4. 4Andrew BoyerFY2025
  5. 5Jason DalyFY2025
  6. 6Nikita ShahFY2025

Named executives and their total pay, from the Summary Compensation Table of the latest proxy.

Pay

See all

Amneal Pharmaceuticals paid its 6 named executives $29.3M in total in FY2025 (Dec). CEO Chintu Patel was paid $8.7M of that.

Name
Chintu PatelCo-Chief Executive Officer
Chirag PatelCo-Chief Executive Officer and President
Anastasios KonidarisEVP & Chief Financial Officer
Andrew BoyerEVP, Chief Commercial Officer - Generics
Jason DalyEVP, Chief Legal Officer & Secretary
Nikita ShahEVP, Chief Human Resources Officer

of each named executive, from the Summary Compensation Table of each proxy.

Peers14

See all

The FY2025 (Dec) proxy of Amneal Pharmaceuticals names 14 peer companies for pay. Pay versus performance data of Amneal Pharmaceuticals for that year is not on file, so it has no rank.

The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year.

Activity

  1. Pay
    Amneal Pharmaceuticals CHRO pay rose 15% to $2.7M. The stock rose 59% in FY2025 (Dec).
    DEF 14A
  2. Pay
    Amneal Pharmaceuticals General counsel pay rose 20% to $2.9M. The stock rose 59% in FY2025 (Dec).
    DEF 14A
  3. Pay
    Amneal Pharmaceuticals CEO pay rose 21% to $8.7M. The stock rose 59% in FY2025 (Dec).
    DEF 14A
  4. Pay
    Amneal Pharmaceuticals CEO pay rose 21% to $8.7M. The stock rose 59% in FY2025 (Dec).
    DEF 14A
  5. Pay
    Amneal Pharmaceuticals CFO pay rose 15% to $3.3M. The stock rose 59% in FY2025 (Dec).
    DEF 14A
  6. Pay
    Amneal Pharmaceuticals CHRO pay rose 55% to $2.4M. The stock rose 30% in FY2024 (Dec).
    DEF 14A
  7. Pay
    Amneal Pharmaceuticals General counsel pay rose 77% to $2.4M. The stock rose 30% in FY2024 (Dec).
    DEF 14A
  8. Pay
    Amneal Pharmaceuticals CEO pay rose 203% to $7.2M. The stock rose 30% in FY2024 (Dec).
    DEF 14A
  9. Pay
    Amneal Pharmaceuticals CEO pay rose 204% to $7.2M. The stock rose 30% in FY2024 (Dec).
    DEF 14A
  10. Pay
    Amneal Pharmaceuticals Division head pay rose 44% to $2.8M. The stock rose 30% in FY2024 (Dec).
    DEF 14A
  11. Pay
    Amneal Pharmaceuticals CFO pay rose 51% to $2.9M. The stock rose 30% in FY2024 (Dec).
    DEF 14A
  12. Pay
    Amneal Pharmaceuticals CHRO pay fell 32% to $1.5M. The stock rose 205% in FY2023 (Dec).
    DEF 14A
  13. Pay
    Amneal Pharmaceuticals General counsel pay fell 22% to $1.3M. The stock rose 205% in FY2023 (Dec).
    DEF 14A
  14. Pay
    Amneal Pharmaceuticals CEO pay fell 53% to $2.4M. The stock rose 205% in FY2023 (Dec).
    DEF 14A
  15. Pay
    Amneal Pharmaceuticals CEO pay fell 53% to $2.4M. The stock rose 205% in FY2023 (Dec).
    DEF 14A
  16. Pay
    Amneal Pharmaceuticals Division head pay fell 28% to $1.9M. The stock rose 205% in FY2023 (Dec).
    DEF 14A
  17. Pay
    Amneal Pharmaceuticals CFO pay fell 31% to $1.9M. The stock rose 205% in FY2023 (Dec).
    DEF 14A

Filings6

See all
Proxy statementDEF 14AMar 25, 2026FY2025
Annual report10-KFeb 27, 2026FY2025
Proxy statementDEF 14AMar 25, 2025FY2024
Annual report10-KFeb 28, 2025FY2024
Proxy statementDEF 14AMar 22, 2024FY2023
Annual report10-KMar 14, 2024FY2023
For the press:Download CSVDownload PNGHow to use our data